Search
Tenofovir
go.drugbank.com/drugs/DB14126Investigational[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. … [A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order
Mixtures: EMTRICITABINA 200 MG TENOFOVIR 300 MG, EMTRICITABINA 200 MG TENOFOVIR 300 MGPegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and [agalsidase beta], pegunigalsidase alfa uses a plant cell-based protein expression system, leading
Decamethonium
go.drugbank.com/drugs/DB01245ApprovedIt is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.
Categories: Bis-Trimethylammonium CompoundsEthinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnEthinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient. Nevertheless, the medicatio...
Avacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigational[L47696] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individuals affected. … It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA).
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27264] Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.[A27263]
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMK-0736
go.drugbank.com/drugs/DB15209InvestigationalMK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).
Turpentine
go.drugbank.com/drugs/DB11120ApprovedIt is used as a solvent and base material in organic synthesis reactions. … Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin.
Mixtures: BUĞUMENTOL BUĞU, 40 G, KATALJİN BUHARLAŞAN MERHEM, 40 GSulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years.
Mixtures: TP-SULTRIXIN 40/200MG/ML SOLUTION, TP-SULTRIME 80/400MG/G POWDERCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors